BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 16983933)

  • 1. Impact on peritoneal membrane of use of icodextrin-based dialysis solution in peritoneal dialysis patients.
    Moriishi M; Kawanishi H; Tsuchiya S
    Adv Perit Dial; 2006; 22():24-8. PubMed ID: 16983933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Icodextrin and intraperitoneal inflammation.
    Moriishi M; Kawanishi H
    Perit Dial Int; 2008 Jun; 28 Suppl 3():S96-S100. PubMed ID: 18552274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of icodextrin-based peritoneal dialysis solution on peritoneal membrane.
    Moriishi M; Kawanishi H; Watanabe H; Tsuchiya S
    Adv Perit Dial; 2005; 21():21-4. PubMed ID: 16686279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between peritoneal permeability and ultrafiltration volume with icodextrin-based peritoneal dialysis solution.
    Moriishi M; Kawanishi H; Watanabe H; Tsuchiya S
    Adv Perit Dial; 2004; 20():166-9. PubMed ID: 15384820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A case of encapsulating peritoneal sclerosis suspected to result from the use of icodextrin peritoneal solution.
    Kawanishi H; Shintaku S; Shishida M; Morrishi M; Tsuchiya S; Dohi K
    Adv Perit Dial; 2009; 25():45-9. PubMed ID: 19886316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Markers in peritoneal effluent for withdrawal from peritoneal dialysis: multicenter prospective study in Japan.
    Kawanishi H; Fujimori A; Tsuchida K; Takemoto Y; Tomo T; Minakuchi J; Yamamoto T; Kim M; Numata A; Choh S; Naito H;
    Adv Perit Dial; 2005; 21():134-8. PubMed ID: 16686304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peritoneal dialysis patients with high effluent fibrin degradation products.
    Moriishi M; Kawanishi H; Tsuchiya S
    Adv Perit Dial; 2009; 25():41-4. PubMed ID: 19886315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between effluent levels of beta(2)-microglobulin and peritoneal injury markers in 7.5% icodextrin-based peritoneal dialysis solution.
    Minami S; Hora K; Kamijo Y; Higuchi M
    Ther Apher Dial; 2007 Aug; 11(4):296-300. PubMed ID: 17661836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of combination therapy with peritoneal dialysis and hemodialysis on peritoneal function.
    Moriishi M; Kawanishi H; Tsuchiya S
    Adv Perit Dial; 2010; 26():67-70. PubMed ID: 21348383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intraperitoneal IL-6 signaling in incident patients treated with icodextrin and glucose bicarbonate/lactate-based peritoneal dialysis solutions.
    Opatrna S; Lysak D; Trefil L; Parker C; Topley N
    Perit Dial Int; 2012; 32(1):37-44. PubMed ID: 22302924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Peritoneal equilibrium test using icodextrin and glucose at different concentrations].
    Guerrero A; Montes R; Martín-Herrera C; Ruiz A; Gallego T; Delgado-Pecellín C; Benítez M; Torán CD
    Nefrologia; 2002; 22(4):340-7. PubMed ID: 12369125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrin degradation products are a useful marker for the risk of encapsulating peritoneal sclerosis.
    Moriishi M; Kawanishi H
    Adv Perit Dial; 2008; 24():56-9. PubMed ID: 18986002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of a 7.5% icodextrin peritoneal dialysis solution in patients treated with automated peritoneal dialysis.
    Plum J; Gentile S; Verger C; Brunkhorst R; Bahner U; Faller B; Peeters J; Freida P; Struijk DG; Krediet RT; Grabensee B; Tranaeus A; Filho JC
    Am J Kidney Dis; 2002 Apr; 39(4):862-71. PubMed ID: 11920355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A preceding exchange with polyglucose versus glucose solution modifies peritoneal equilibration test results.
    Lilaj T; Dittrich E; Puttinger H; Schneider B; Haag-Weber M; Hörl WH; Vychytil A
    Am J Kidney Dis; 2001 Jul; 38(1):118-26. PubMed ID: 11431191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peritoneal equilibration test with conventional 'low pH/high glucose degradation product' or with biocompatible 'normal pH/low glucose degradation product' dialysates: does it matter?
    Van Overmeire L; Goffin E; Krzesinski JM; Saint-Remy A; Bovy P; Cornet G; Bovy C
    Nephrol Dial Transplant; 2013 Jul; 28(7):1946-51. PubMed ID: 23223220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peritoneal accumulation of advanced glycosylation end-products in diabetic rats on dialysis with icodextrin.
    Lee JH; Reddy DK; Saran R; Moore HL; Twardowski ZJ; Nolph KD; Khanna R
    Perit Dial Int; 2000; 20 Suppl 5():S39-47. PubMed ID: 11229611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Biocompatibility of Neutral Icodextrin Peritoneal Dialysis Fluid.
    Shimada S; Mori T; Koizumi K; Sato S; Oba-Yabana I; Ohsaki Y; Sato E; Naganuma E; Kurasawa N; Tsuchikawa M; Ito S
    Adv Perit Dial; 2016; 32():46-50. PubMed ID: 28988589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between ultrafiltrate volume with icodextrin and peritoneal transport pattern according to the peritoneal equilibration test.
    Araújo Teixeira MR; Pecoits-Filho RF; Romão Junior JE; Sabbaga E; Marcondes MM; Abensur H
    Perit Dial Int; 2002; 22(2):229-33. PubMed ID: 11990408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of the effectiveness, safety, and biocompatibility of icodextrin in automated peritoneal dialysis. The Dextrin in APD in Amsterdam (DIANA) Group.
    Posthuma N; ter Wee PM; Donker AJ; Oe PL; Peers EM; Verbrugh HA
    Perit Dial Int; 2000; 20 Suppl 2():S106-13. PubMed ID: 10911654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of icodextrin in peritoneal dialysis patients.
    Moberly JB; Mujais S; Gehr T; Hamburger R; Sprague S; Kucharski A; Reynolds R; Ogrinc F; Martis L; Wolfson M
    Kidney Int Suppl; 2002 Oct; (81):S23-33. PubMed ID: 12230479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.